Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GV1001 in Moderate Alzheimer's Disease
NCT03959553Phase 2Withdrawn
- Sponsor
- GemVax & KAEL Co., Ltd.
- Start
- Sep 2019
- Primary completion
- Aug 2021
- Modality
- Peptides, Vaccines & Immunotherapeutics
01
Overview
Phase 2, randomised, double-blind trial of tertomotide in Alzheimer's disease (AD) (3 arms), sponsored by GemVax & KAEL Co., Ltd. Primary endpoint: Alzheimer's Disease Assessment Scale-cognitive at Week 26. Planned start Sep 2019; status: withdrawn.
02
Drugs
tertomotide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03959553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03959553.